Saturday 17 October 2026
Export HROW’s income statement to Excel — free account
Harrow, Inc.
HROW Healthcare Drug Manufacturers Specialty & Generic
Harrow, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $272.3 million, up 36.4% from fiscal 2024. In the quarter to June 2026, revenue grew 10.9%, EPS fell 428.6%, free cash flow fell 838.8% and total debt rose 659.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
27.28
1.47
−5.11%
Follow HROW
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 8.62 | 389.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
6 | 4 | 7 | 6 | 4 | 5 | 5 | 4 | 4 | 6 |
P/S ratio |
1.58 | 1.29 | 3.01 | 3.85 | 3.63 | 3.19 | 4.58 | 2.99 | 5.99 | 6.61 |
Altman Z-Score |
(4.01) | (4.65) | 1.93 | 3.06 | 3.10 | 1.64 | 2.26 | 1.07 | 2.59 | 3.84 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.12 |
Altman Z″-Score (non-manufacturers) |
(11.62) | (14.57) | (1.77) | (1.08) | 0.02 | 0.48 | 2.19 | 0.81 | 0.77 | 1.29 |
Beneish M-Score |
(2.35) | (3.01) | (0.92) | (2.34) | (2.49) | (3.15) | (2.76) | 0.78 | (1.03) | (3.04) |
P/Operating CF |
(14.06) | (117.85) | (3,464.26) | 119.26 | (313.85) | (155.15) | (109.34) | 44.82 | (67.27) | 214.16 |
P/B ratio |
4.89 | 13.25 | 5.04 | 7.19 | 6.62 | 21.15 | 14.90 | 5.54 | 17.26 | 34.58 |
Price to Tangible BV |
25.53 | 0.00 | 6.41 | 7.96 | 7.23 | 0.00 | 127.51 | 0.00 | 0.00 | 0.00 |
EV/Sales |
1.59 | 1.69 | 2.62 | 3.55 | 3.30 | 3.53 | 4.65 | 3.82 | 6.87 | 7.25 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 44.96 | 54.63 | 64.73 | 29.45 | 49.78 | 36.42 |
EV/Operating CF |
(2.82) | (5.13) | 157.87 | 191.07 | (146.52) | 50.39 | 241.69 | 129.37 | (61.81) | 45.04 |
EV/FCF |
(1.73) | (4.62) | (71.54) | (205.57) | (77.45) | (23.63) | (10,844.38) | (3.34) | (22.54) | 46.20 |
Quick Ratio |
1.21 | 1.00 | 2.54 | 2.62 | 3.28 | 5.67 | 5.80 | 2.41 | 1.79 | 1.91 |
Current Ratio |
1.49 | 1.53 | 2.76 | 2.93 | 3.80 | 6.24 | 6.35 | 2.83 | 2.08 | 2.20 |
Net Debt/EBITDA |
(0.34) | (1.18) | 4.71 | 9.57 | (4.59) | 4.48 | 0.36 | 6.11 | 6.25 | 3.14 |
Debt/Assets |
50.23% | 64.08% | 30.83% | 24.80% | 28.35% | 72.88% | 66.19% | 59.55% | 56.44% | 60.87% |
Debt/Equity |
2.13 | 5.86 | 0.62 | 0.53 | 0.61 | 6.56 | 3.82 | 2.64 | 3.17 | 4.67 |
Asset Turnover |
0.96 | 1.05 | 1.13 | 0.94 | 0.84 | 0.93 | 0.69 | 0.55 | 0.57 | 0.69 |
Operating CF/Net income |
0.59 | 0.73 | 0.05 | 5.65 | 0.33 | (0.27) | (0.12) | (0.16) | 1.27 | (8.54) |
Capex/Depreciation |
(3.00) | (0.35) | (0.90) | (0.58) | (0.31) | (5.18) | (0.39) | (9.28) | (2.06) | (0.05) |
Interest Coverage |
(5.73) | (4.02) | (1.91) | (1.92) | 0.17 | 0.30 | 0.26 | 0.02 | 0.39 | 1.26 |
| (756.37%) | (264.95%) | 106.88% | 0.64% | (12.38%) | (97.88%) | (73.80%) | (50.00%) | (25.03%) | (8.47%) | |
| (92.26%) | (46.85%) | 39.87% | 0.31% | (5.76%) | (23.72%) | (11.02%) | (10.40%) | (4.99%) | (1.30%) | |
ROIC |
(89.71%) | (55.40%) | (27.77%) | (25.14%) | 2.32% | 3.16% | 4.06% | 0.16% | 2.28% | 8.58% |
Return on Tangible Assets |
(157.19%) | (129.61%) | 53.54% | 0.58% | (9.86%) | (34.17%) | (13.66%) | (26.06%) | (17.13%) | (4.33%) |
Average Days of Receivables |
53.46 | 20.84 | 16.89 | 14.33 | 19.88 | 22.51 | 25.75 | 101.66 | 212.79 | 148.65 |
Research and Development Expense of Revenue |
3.71% | 1.54% | 1.99% | 4.07% | 4.94% | 15.29% | 3.44% | 5.11% | 6.13% | 7.69% |
Selling, General and Administrative Expense of Revenue |
125.12% | 93.45% | 70.68% | 64.67% | 63.94% | 57.01% | 65.74% | 63.82% | 64.66% | 56.16% |
Intangible Assets out of Total Assets |
0.19 | 0.21 | 0.11 | 0.05 | 0.04 | 0.16 | 0.15 | 0.51 | 0.48 | 0.44 |
Share Based Compensation of Revenue |
18.42% | 10.99% | 6.37% | 3.95% | 5.85% | 7.93% | 9.00% | 12.06% | 8.83% | 4.59% |
Graham Net Nets |
(0.19) | (0.36) | 0.07 | 0.02 | 0.06 | (0.12) | (0.03) | (0.26) | (0.11) | (0.08) |
Graham Number |
0.00 | 0.00 | 4.10 | 0.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(61.13%) | (34.68%) | 11.60% | 0.26% | (2.04%) | (7.87%) | (3.52%) | (6.28%) | (1.46%) | (0.31%) |
Free Cash Flow Yield |
(58.31%) | (28.18%) | (1.22%) | (0.45%) | (1.17%) | (4.69%) | (0.01%) | (38.15%) | (5.09%) | 2.37% |
Revenue per Share |
1.56 | 1.34 | 1.89 | 2.02 | 1.89 | 2.71 | 3.23 | 3.99 | 5.60 | 7.41 |
Operating CF per Share |
(0.88) | (0.44) | 0.03 | 0.04 | (0.04) | 0.19 | 0.06 | 0.12 | (0.62) | 1.19 |
Capex per Share |
(0.56) | (0.05) | (0.10) | (0.07) | (0.04) | (0.59) | (0.06) | (4.68) | (1.08) | (0.03) |
Free Cash Flow per Share |
(1.44) | (0.49) | (0.07) | (0.03) | (0.08) | (0.41) | 0.00 | (4.56) | (1.71) | 1.16 |
Cash per Share |
0.71 | 0.21 | 1.29 | 1.19 | 1.27 | 1.89 | 3.71 | 2.54 | 1.33 | 1.98 |
Shareholders Equity per Share |
0.50 | 0.13 | 1.13 | 1.08 | 1.04 | 0.41 | 0.99 | 2.16 | 1.94 | 1.42 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.50 | 0.13 | 1.13 | 1.08 | 1.04 | 0.41 | 0.99 | 2.16 | 1.94 | 1.42 |
Free Cash Flow |
(18.35) | (9.76) | (1.52) | (0.88) | (2.08) | (10.84) | (0.04) | (148.71) | (60.88) | 42.76 |
Working Capital |
4.85 | 3.03 | 20.94 | 23.76 | 30.18 | 50.94 | 99.63 | 90.14 | 98.31 | 115.45 |
Capital Expenditures |
(7.14) | (0.96) | (2.20) | (1.83) | (0.98) | (15.92) | (1.74) | (152.55) | (38.67) | (1.10) |
Net Current Asset Value |
(6.06) | (12.50) | 8.14 | 4.38 | 10.34 | (26.74) | (11.88) | (102.27) | (130.02) | (135.64) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 418.64 | 158.66 | 214.74 | 1,152.64 | 155.55 | 64.74 |
Capex to Sales |
0.36 | 0.04 | 0.05 | 0.04 | 0.02 | 0.22 | 0.02 | 1.17 | 0.19 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 461.40 | 143.23 | 211.50 | 904.34 | 135.58 | 59.03 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.33 | 0.44 | 0.39 | 0.59 | 0.83 | 0.98 | 1.28 | 4.67 | 5.02 | 7.28 |
Cash ROIC |
(62.92%) | (44.06%) | (2.22%) | (1.22%) | (2.74%) | (8.13%) | (0.02%) | (43.86%) | (18.11%) | 11.61% |
Accounts Receivable Turnover |
10.60 | 12.03 | 24.03 | 26.08 | 20.93 | 20.32 | 16.53 | 6.13 | 2.62 | 2.40 |
Accounts Payable Turnover |
2.83 | 3.64 | 3.26 | 2.40 | 2.49 | 3.55 | 2.52 | 2.07 | 1.49 | 1.63 |
Inventory Turnover |
6.04 | 6.60 | 8.09 | 6.52 | 3.98 | 4.45 | 4.72 | 4.55 | 4.57 | 5.61 |
Average Days of Payables |
131.36 | 105.00 | 138.08 | 167.84 | 99.23 | 126.99 | 198.02 | 226.34 | 306.90 | 225.44 |
Days of Inventory on Hand |
68.35 | 60.78 | 40.52 | 71.94 | 99.99 | 84.51 | 94.06 | 100.06 | 79.32 | 72.66 |
Average Receivables |
1.88 | 2.23 | 1.72 | 1.96 | 2.34 | 3.57 | 5.36 | 21.26 | 76.32 | 113.63 |
Average Payables |
3.47 | 3.71 | 5.07 | 6.98 | 5.82 | 5.13 | 10.05 | 19.18 | 32.99 | 41.68 |
Average Inventory |
1.63 | 2.05 | 2.04 | 2.57 | 3.63 | 4.09 | 5.38 | 8.70 | 10.78 | 12.11 |
Average Assets |
20.69 | 25.58 | 36.68 | 54.27 | 58.28 | 77.90 | 127.85 | 234.77 | 350.57 | 394.23 |
Average Common Equity |
2.52 | 4.52 | 13.68 | 26.08 | 27.12 | 18.88 | 19.09 | 48.83 | 69.85 | 60.69 |
Columns are period end dates